Management of 2-Week-Old Neonate with Confirmed Oral HSV
This 2-week-old neonate with a confirmed cold sore requires immediate high-dose intravenous acyclovir (20 mg/kg three times daily) for 14 days, along with comprehensive diagnostic evaluation to rule out disseminated or CNS disease. 1
Immediate Diagnostic Workup Required
Before or concurrent with starting treatment, obtain:
- Cultures from multiple sites: blood, skin vesicles, mouth/nasopharynx, eyes, urine, and stool/rectum (positive cultures >48 hours after birth indicate viral replication, not just contamination) 1
- CSF analysis with HSV PCR: This is critical because 60-75% of neonates with disseminated disease have CNS involvement, and approximately 60% of infants with CNS or disseminated disease lack visible vesicular rash 1
- Liver function tests and complete blood count: To assess for disseminated disease involving liver and other organs 1
Treatment Protocol
For Localized Skin, Eye, and Mouth Disease (SEM):
- IV acyclovir 20 mg/kg/dose three times daily for 14 days 1
- This is the minimum duration; do not use oral acyclovir in neonates with active disease
If CNS or Disseminated Disease is Found:
- Extend treatment to 21 days 1
- Do not discontinue therapy until repeat CSF HSV DNA PCR is negative at day 19-21 1
Critical Clinical Reasoning
Why aggressive treatment is mandatory: Even with what appears to be localized oral disease, 2-6% of infants with SEM disease develop neurologic sequelae despite apparently successful treatment 1. The vesicular rash is only present in approximately 80% of children with localized disease and only 60% with CNS/disseminated disease 1, meaning absence of widespread lesions does not exclude serious disease.
Timing matters: Neonatal HSV typically presents at 9-11 days of life, and this infant at 2 weeks is in the typical window 1. The maternal cold sore suggests postnatal transmission rather than intrapartum exposure, but the management remains the same.
Monitoring During Treatment
- Renal function: Check creatinine clearance regularly; acyclovir is nephrotoxic and requires dose adjustment for renal insufficiency 1
- Neutrophil count: Major toxicity in neonates receiving high-dose acyclovir is neutropenia (ANC <1,000/mm³), occurring in up to 46% of infants 1
- Hydration: Maintain adequate fluid status to minimize crystalluria and obstructive nephropathy risk 2
Common Pitfalls to Avoid
Do not use oral acyclovir for acute neonatal HSV: Pediatric experience with oral acyclovir is extremely limited in children <2 years, and it does not achieve adequate CSF levels 1, 2
Do not assume localized disease without full workup: The clinical presentation can be deceptive—always obtain CSF PCR even if the infant appears well with only oral lesions 1
Do not stop treatment early: Even if the infant appears clinically improved, complete the full 14-day course for SEM disease. For CNS involvement, treatment must continue until CSF PCR is negative 1
Do not delay treatment for test results: If there is any clinical suspicion while awaiting confirmatory testing, empiric acyclovir should be started immediately 2
Post-Treatment Considerations
- Cutaneous recurrences are common: Even with successful treatment, neonates with skin lesions may have cutaneous recurrences during the first 6 months 1
- Long-term suppressive therapy: While under investigation, routine suppressive oral acyclovir following acute treatment is not yet standard but may be considered in consultation with pediatric infectious disease specialists 1, 3, 4
- Neurodevelopmental follow-up: All infants treated for neonatal HSV require long-term monitoring for neurologic sequelae 1